Mon. 5 Feb 2024, 8:20am ET
Benzinga
Biotech, News, General
Oragenics' lead drug candidate, ONP-002, is a new chemical entity (NCE) designed to target the brain through self-propelled powdered delivery into the nasal cavity. A 40-patient Phase I study showed ONP-002 to be safe and well-tolerated.